Pseudomyxoma Peritonei

Pseudomyxoma Peritonei - StatPearls - NCBI Bookshelf

  • mucinous abdominal cancer: “jelly belly”
  • Risk factors: familial adenomatous polyposis
  • omental cake

Peritoneal Carcinomatosis

Abdominal Compartment Syndrome

Acute Mesenteric Ischemia

Portal Vein Thrombosis

Pneumatosis Intestinalis

Pneumobilia

  • Bad bad (normally, air in abd = perf or infection)
  • Normal in RNYHJ (Roux en Y Hepaticojejunostomy) d/t new anatomy

Desmoid Tumors and FAP

Quick Reference
TopicSummary
ConditionDesmoid tumors in Familial Adenomatous Polyposis (FAP)
Key Association~10–15% of FAP patients develop desmoid tumors
LocationPrimarily intra-abdominal (mesenteric, retroperitoneal, abdominal wall)
BehaviorLocally aggressive, non-metastatic
Risk FactorsFamily history of desmoids, extracolonic manifestations, certain APC genotypes
Management StrategyMultidisciplinary; non-surgical treatments preferred first-line
Preferred Initial TreatmentMedical: NSAIDs, anti-estrogens, TKIs (e.g., sorafenib), low-dose chemo, observation
Surgical Indications2nd line: Easily resectable abdominal wall desmoids or complications unresponsive to medical therapy
Pathophysiology
  • APC Mutations in FAP lead to dysregulated Wnt/β-catenin signaling, predisposing to both colorectal adenomas and intra-abdominal desmoid tumors.
  • Desmoid tumors are fibroblastic proliferations that are locally invasive but lack metastatic potential.
  • In sporadic desmoids, CTNNB1 (β-catenin) mutations drive tumorigenesis via the same Wnt pathway, and are mutually exclusive with APC mutations.
  • Desmoid formation is often triggered by surgical trauma, especially post-colectomy in FAP patients.
Epidemiology
  • FAP prevalence: ~1 in 8,000–10,000 individuals.
  • Desmoid tumors in FAP: Occur in 10–15% of patients, often at a younger age than sporadic cases.
  • Sporadic desmoid tumors: Rare, more often extra-abdominal, associated with CTNNB1 mutations.
  • Desmoid-related mortality in FAP: Accounts for up to 21% of deaths.
  • Additional APC-related conditions: Include gastric polyposis, duodenal polyps, hepatoblastoma, medulloblastoma (Turcot syndrome), and thyroid/adrenal tumors.
Diagnosis
  • Presentation: May be asymptomatic or cause pain, bowel obstruction, or organ compromise due to local invasion.
  • Timing: Frequently post-operative (e.g., post-colectomy in FAP).
  • Location clues: FAP-associated = intra-abdominal; Sporadic = often extra-abdominal.
  • Genetic Testing: APC mutation analysis in FAP; CTNNB1 genotyping for sporadic desmoids.
Treatment

General Approach

  • Managed at specialized centers using a multidisciplinary strategy.
  • Observation is appropriate for stable, asymptomatic tumors

Medical Therapy (Preferred First-line for Intra-abdominal Desmoids)

  • NSAIDs
  • Anti-estrogens
  • Tyrosine kinase inhibitors (TKIs): e.g., sorafenib, imatinib
  • Low-dose chemotherapy: methotrexate/vinblastine or anthracycline regimens
  • Emerging agents: γ-secretase inhibitors (e.g., nirogacestat)
    Surgery
  • Reserved for:
  • Abdominal wall desmoids that are easily resectable
  • Intra-abdominal tumors with intractable symptoms or complications unresponsive to medical therapy
References
  1. Poylin VY, Shaffer VO, Felder SI, et al. Diseases of the Colon and Rectum. 2024;67(2):213–227. doi:10.1097/DCR.0000000000003072
  2. Aoun RJN, Kalady MF. Familial Cancer. 2025;24(3):56. doi:10.1007/s10689-025-00481-9
  3. DE Marchis ML, Tonelli F, Quaresmini D, et al. Anticancer Res. 2017;37(7):3357–3366. doi:10.21873/anticanres.11702
  4. Al-Sukhni E, Shapiro J, Suraweera H, et al. Ann Surg Oncol. 2023;30(8):5142–5149. doi:10.1245/s10434-023-13675-1
  5. Kasper B, Baldini EH, Bonvalot S, et al. JAMA Oncol. 2024;10(8):1121–1128. doi:10.1001/jamaoncol.2024.1805
  6. Desurmont T, Lefèvre JH, Shields C, et al. Familial Cancer. 2015;14(1):31–9. doi:10.1007/s10689-014-9760-1
  7. Gounder MM, Mahoney MR, Van Tine BA, et al. N Engl J Med. 2018;379(25):2417–2428. doi:10.1056/NEJMoa1805052
  8. Riedel RF, Agulnik M. Cancer. 2022;128(16):3027–3040. doi:10.1002/cncr.34332

Let me know if you’d like a printable PDF version or figures/diagrams added.